Pavel Raifeld C.F.A. Net Worth

The estimated Net Worth of Pavel Raifeld is at least $564 ezer dollars as of 10 March 2023. Mr Raifeld owns over 3,000 units of Innoviva Inc stock worth over $190,101 and over the last 4 years he sold INVA stock worth over $0. In addition, he makes $373,968 as Chief Exec. Officer at Innoviva Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A INVA stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Innoviva Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of INVA stock worth $32,610 on 10 March 2023.

The largest trade he's ever made was buying 3,000 units of Innoviva Inc stock on 10 March 2023 worth over $32,610. On average, Mr trades about 750 units every 0 days since 2021. As of 10 March 2023 he still owns at least 9,799 units of Innoviva Inc stock.

You can see the complete history of Mr Raifeld stock trades at the bottom of the page.

Mr. Pavel Raifeld C.F.A. biography

Pavel Raifeld C.F.A. is the Chief Exec. Officer at Innoviva Inc.

What is the salary of Mr A?

As the Chief Exec. Officer of Innoviva Inc, the total compensation of Mr A at Innoviva Inc is $373,968. There are 2 executives at Innoviva Inc getting paid more, with Marianne Zhen having the highest compensation of $551,918.

How old is Mr A?

Mr A is 37, he's been the Chief Exec. Officer of Innoviva Inc since . There are 7 older and no younger executives at Innoviva Inc. The oldest executive at Innoviva Inc is Jules Haimovitz, 69, who is the Independent Director.

Insiders trading at Innoviva Inc

Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital... és Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.

What does Innoviva Inc do?

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.

Complete history of Mr Raifeld stock trades at Innoviva Inc

Innoviva Inc executives and stock owners

Innoviva Inc executives and other stock owners filed with the SEC include:

• Marianne Zhen,
  Chief Accounting Officer
• Marianne Zhen CPA,
  Chief Accounting Officer
• Pavel Raifeld C.F.A.,
  Chief Exec. Officer
• George Bickerstaff,
  Independent Director
• Jules Haimovitz,
  Independent Director
• Odysseas Kostas,
  Independent Chairman of the Board
• Sarah Schlesinger,
  Independent Director
• Mark DiPaolo,
  Independent Director
• Pavel Raifeld,
  Chief Executive Officer
• Paul Pepe,
  Director
• Michael W Aguiar,
  President & Chief Exec Officer
• Barbara Gayle Duncan,
  Director
• William H Waltrip,
  Director
• Theodore L Jr Witek,
  Sr. VP & Chief Scientific Off.
• Cathy Friedman,
  Director
• James L Tyree,
  Director
• Michael E. Faerm,
  Sr VP & Chief Business Officer
• George B Abercrombie,
  Sr. VP & Chief Comm. Officer
• Patrick G Lepore,
  Director
• Eric D Esparbes,
  SVP and CFO
• Alexander J Sarissa Capital...,
  
• Matthew Ronsheim,
  See Remarks
• Geoffrey Hulme,
  Interim Principal Exec Officer
• Deborah Birx,
  Director
• Plc Gsk,
  10% owner
• Derek A Small,
  Director
• Sapna Srivastava,
  Director
• Margaret Koziel,
  Chief Medical Officer
• Stephen Basso,
  Chief Financial Officer